Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2/3 1

Status

Unknown 3

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 3

Interventions

Gemcitabine 73Fluorouracil 30Oxaliplatin 20Leucovorin 20130-nm albumin-bound paclitaxel 16Capecitabine 14Irinotecan 11Albumin-Bound Paclitaxel 10irinotecan sucrosofate 8Radiotherapy 6Taxes 5Erlotinib Hydrochloride 5folfirinox 4rubitecan 3Surgical Procedures, Operative 3Specimen Handling 3Pancreaticojejunostomy 3Neoadjuvant Therapy 3Drug Therapy 3Cisplatin 3Chemotherapy, Adjuvant 3ruxolitinib 2masitinib 2dehydroftorafur 2Saline Solution 2S 1 (combination) 2Paclitaxel 2GV1001 peptide 2Fentanyl 2Bevacizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Pancreatic Neoplasms × rubitecan × Clear all
NCT00005869 2013-12-04

Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
Gastrointestinal

Pancreatic Neoplasms

NCT00005870 2013-12-04

Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas

National Cancer Institute (NCI)

Phase 3 Unknown
Gastrointestinal

Pancreatic Neoplasms

NCT00005871 2013-12-04

Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡